Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 83 of the 85 references it cites were found in a registry or an index.

Extracellular matrix proteomics identifies molecular signature of symptomatic carotid plaques

Open access

Abstract

BACKGROUND: The identification of patients with high-risk atherosclerotic plaques prior to the manifestation of clinical events remains challenging. Recent findings question histology- and imaging-based definitions of the "vulnerable plaque," necessitating an improved approach for predicting onset of symptoms. METHODS: We performed a proteomics comparison of the vascular extracellular matrix and associated molecules in human carotid endarterectomy specimens from 6 symptomatic versus 6 asymptomatic patients to identify a protein signature for high-risk atherosclerotic plaques. Proteomics data were integrated with gene expression profiling of 121 carotid endarterectomies and an analysis of protein secretion by lipid-loaded human vascular smooth muscle cells. Finally, epidemiological validation of candidate biomarkers was performed in two community-based studies. RESULTS: Proteomics and at least one of the other two approaches identified a molecular signature of plaques from symptomatic patients that comprised matrix metalloproteinase 9, chitinase 3-like-1, S100 calcium binding protein A8 (S100A8), S100A9, cathepsin B, fibronectin, and galectin-3-binding protein. Biomarker candidates measured in 685 subjects in the Bruneck study were associated with progression to advanced atherosclerosis and incidence of cardiovascular disease over a 10-year follow-up period. A 4-biomarker signature (matrix metalloproteinase 9, S100A8/S100A9, cathepsin D, and galectin-3-binding protein) improved risk prediction and was successfully replicated in an independent cohort, the SAPHIR study. CONCLUSION: The identified 4-biomarker signature may improve risk prediction and diagnostics for the management of cardiovascular disease. Further, our study highlights the strength of tissue-based proteomics for biomarker discovery. FUNDING: UK: British Heart Foundation (BHF); King's BHF Center; and the National Institute for Health Research Biomedical Research Center based at Guy's and St Thomas' NHS Foundation Trust and King's College London in partnership with King's College Hospital. Austria: Federal Ministry for Transport, Innovation and Technology (BMVIT); Federal Ministry of Science, Research and Economy (BMWFW); Wirtschaftsagentur Wien; and Standortagentur Tirol.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci86924

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 ECM proteomics of carotid endarterectomies. Volcano plots of differences in abundance in (A) the proteome of the NaCl fraction (n = 12) and (B) the proteome of the GuHCl fraction (n = 12) between symptomatic and asymptomatic patients. Colors represent FDR levels (red, FDR <1%; orange, FDR <5%; green, FDR <10%; blue, FDR ≥10%, by NSAF-PLGEM; FC, fold change), and the labeled dots are those that were significantly differentially expressed between the plaques from symptomatic and asymptomatic patients (FDR <10%). (C) Coexpression network in the NaCl fraction (n = 12) calculated from Pearson correlations with edges defined at FDR <20% (Q values). The sizes of the nodes indicate the level of confidence for the differential expression between plaques from symptomatic and asymptomatic patients, and the colors represent different protein classifications (yellow, growth factors, cytokines, and regulatory factors; green, apolipoproteins; pink, collagens; orange, proteases/peptidases and inhibitors; blue, matricellular proteins and glycoproteins; white, other).
Figure 1 ECM proteomics of carotid endarterectomies. Volcano plots of differences in abundance in (A) the proteome of the NaCl fraction (n = 12) and (B) the proteome of the GuHCl fraction (n = 12) between symptomatic and asymptomatic patients. Colors represent FDR levels (red, FDR <1%; orange, FDR <5%; green, FDR <10%; blue, FDR ≥10%, by NSAF-PLGEM; FC, fold change), and the labeled dots are those that were significantly differentially expressed between the plaques from symptomatic and asymptomatic patients (FDR <10%). (C) Coexpression network in the NaCl fraction (n = 12) calculated from Pearson correlations with edges defined at FDR <20% (Q values). The sizes of the nodes indicate the level of confidence for the differential expression between plaques from symptomatic and asymptomatic patients, and the colors represent different protein classifications (yellow, growth factors, cytokines, and regulatory factors; green, apolipoproteins; pink, collagens; orange, proteases/peptidases and inhibitors; blue, matricellular proteins and glycoproteins; white, other).CC BY · PubMed Central
Figure 2 Comparison between protein and gene expression levels. (A) Schematic for detecting differentially expressed proteins that were also differentially expressed at the mRNA transcript level. (B) Volcano plot of differences in expression between symptomatic and asymptomatic patients (n = 121) for corresponding ECM-associated genes (green, FDR <10%; blue, FDR ≥10%, by limma), and the labeled dots are those that were significantly differentially expressed between the plaques from symptomatic and asymptomatic patients (FDR <10%). (C) Box plots for the 5 molecules in common for protein abundance (NSAF) and normalized gene expression (n = 12, proteomics; n = 121, transcriptomics; FDR <10%). The box plots are as follows: black line, median; box edges, 1st and 3rd quartiles; whiskers, furthest point within 1.5 times the interquartile range.
Figure 2 Comparison between protein and gene expression levels. (A) Schematic for detecting differentially expressed proteins that were also differentially expressed at the mRNA transcript level. (B) Volcano plot of differences in expression between symptomatic and asymptomatic patients (n = 121) for corresponding ECM-associated genes (green, FDR <10%; blue, FDR ≥10%, by limma), and the labeled dots are those that were significantly differentially expressed between the plaques from symptomatic and asymptomatic patients (FDR <10%). (C) Box plots for the 5 molecules in common for protein abundance (NSAF) and normalized gene expression (n = 12, proteomics; n = 121, transcriptomics; FDR <10%). The box plots are as follows: black line, median; box edges, 1st and 3rd quartiles; whiskers, furthest point within 1.5 times the interquartile range.CC BY · PubMed Central
Figure 3 Proteomics of the secretome from lipid-loaded human vascular SMCs. (A) Schematic for detecting differentially expressed ECM proteins that also showed differential secretion in lipid-loaded human vascular SMCs. (B) The proteomics analysis of the conditioned media (“secretome”) showed the LGALS3BP level to be significantly higher in the lipid-loaded versus control SMCs (n = 6, ***P = 0.005, paired t test). The box plot is as follows: black line, median; box edges, 1st and 3rd quartile; whiskers, furthest point within 1.5 times the interquartile range. (C) Immunofluorescence staining for LGALS3BP (red) in early atherosclerosis (human ascending aorta). Autofluorescence of elastin fibers (green). Scale bars: 200 μm. (D) Validation by immunoblotting. Note the co-detection of MMP9, FN1, LGALS3BP, and TNC upon lipid loading. SMCs from two different donors. Gelatin zymography for MMP2 was used as loading control. (E) Human aortic explants were either incubated with 50 pM MMP9 or left untreated for 24 hours. The degradation of FN1, TNC, and LGALS3B was examined by immunoblotting. MMP9 induces degradation of FN1 and TNC but releases LGALS3BP from human aortic explants. Aortic explants were from 2 different donors. Arrows indicate fragmentation products.
Figure 3 Proteomics of the secretome from lipid-loaded human vascular SMCs. (A) Schematic for detecting differentially expressed ECM proteins that also showed differential secretion in lipid-loaded human vascular SMCs. (B) The proteomics analysis of the conditioned media (“secretome”) showed the LGALS3BP level to be significantly higher in the lipid-loaded versus control SMCs (n = 6, ***P = 0.005, paired t test). The box plot is as follows: black line, median; box edges, 1st and 3rd quartile; whiskers, furthest point within 1.5 times the interquartile range. (C) Immunofluorescence staining for LGALS3BP (red) in early atherosclerosis (human ascending aorta). Autofluorescence of elastin fibers (green). Scale bars: 200 μm. (D) Validation by immunoblotting. Note the co-detection of MMP9, FN1, LGALS3BP, and TNC upon lipid loading. SMCs from two different donors. Gelatin zymography for MMP2 was used as loading control. (E) Human aortic explants were either incubated with 50 pM MMP9 or left untreated for 24 hours. The degradation of FN1, TNC, and LGALS3B was examined by immunoblotting. MMP9 induces degradation of FN1 and TNC but releases LGALS3BP from human aortic explants. Aortic explants were from 2 different donors. Arrows indicate fragmentation products.CC BY · PubMed Central
Figure 4 Biomarker candidates in tissue and plasma. (A) Immunohistochemistry staining for LGALS3BP, S100A8/A9, CHI3L1, and MMP9 plus SMC (SMA, CNN1) and macrophage (CD68) markers. Scale bars: 500 μm. (B) Association between the biomarker candidates and atherosclerosis (n = 560) and CVD (n = 685) in the Bruneck study. Direction and strength of associations are coded by color and significance levels by size of frames. ORs are derived from logistic regression analysis, and hazard ratios from Cox models. ORs and hazard ratios are expressed for a 1-SD higher loge-transformed level of the given marker. Full details are presented in Supplemental Tables 6 and 7. Model 1 (M1) was adjusted for age (years) and sex. M2 was additionally controlled for standard vascular risk factors, including LDL cholesterol (mg/dl), HDL cholesterol (mg/dl), high-sensitivity CRP (mg/l), diabetes mellitus (0 vs. 1), hypertension (0 vs. 1), smoking (pack-years), and body mass index (kg/m2). *Additionally adjusted for atherosclerosis score (mm).
Figure 4 Biomarker candidates in tissue and plasma. (A) Immunohistochemistry staining for LGALS3BP, S100A8/A9, CHI3L1, and MMP9 plus SMC (SMA, CNN1) and macrophage (CD68) markers. Scale bars: 500 μm. (B) Association between the biomarker candidates and atherosclerosis (n = 560) and CVD (n = 685) in the Bruneck study. Direction and strength of associations are coded by color and significance levels by size of frames. ORs are derived from logistic regression analysis, and hazard ratios from Cox models. ORs and hazard ratios are expressed for a 1-SD higher loge-transformed level of the given marker. Full details are presented in Supplemental Tables 6 and 7. Model 1 (M1) was adjusted for age (years) and sex. M2 was additionally controlled for standard vascular risk factors, including LDL cholesterol (mg/dl), HDL cholesterol (mg/dl), high-sensitivity CRP (mg/l), diabetes mellitus (0 vs. 1), hypertension (0 vs. 1), smoking (pack-years), and body mass index (kg/m2). *Additionally adjusted for atherosclerosis score (mm).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 85 references

Cited by

See all 174

Metadata

Authors
Langley, S. R., Willeit, K., Didangelos, A., Matic, L. P., Skroblin, P., Barallobre-Barreiro, J., Lengquist, M., Rungger, G., Kapustin, A., Kedenko, L., Molenaar, C., Lu, R., Barwari, T., Suna, G., Yin, X., Iglseder, B., Paulweber, B., Willeit, P., Shalhoub, J., Pasterkamp, G., Davies, A. H., Monaco, C., Hedin, U., Shanahan, C. M., Willeit, J., Kiechl, S., & Mayr, M.
Affiliations
  • King's College London (GB)
  • Innsbruck Medical University (AT)
  • Karolinska Institutet (SE)
  • Krankenhaus Bruneck (IT)
  • Paracelsus Medical University (AT)
  • Imperial College London (GB)
  • University Medical Center Utrecht (NL)
  • University of Oxford (GB)
Corresponding author
Mayr, Manuel
Venue
Journal of Clinical Investigation
Published
2017-03-20
Volume
127
Issue
4
Pages
1546-1560
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2595645464
Cited by
174
References
85
Citations by year
2026: 20 · 2025: 16 · 2024: 26 · 2023: 17 · 2022: 20 · 2021: 18 · 2020: 20 · 2019: 13 · 2018: 13 · 2017: 11
FWCI
12.89
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Journal of Clinical Investigation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • National University of Singapore (submittedVersion, cc-by)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
  • Figshare (submittedVersion, cc-by)
  • ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
  • Research Portal (King's College London) (submittedVersion, cc-by)
  • Leicester Research Archive (University of Leicester) (submittedVersion, cc-by)
  • Spiral (Imperial College London) (submittedVersion, cc-by)
Funders
  • National Institute for Health and Care Research
  • British Heart Foundation (FS/13/2/29892, PG/11/46/28979, RG/17/2/32808, CH/16/3/32406, RG/16/14/32397, RG/11/14/29056)
  • King's College London
  • European Commission
  • Austrian Science Fund (J-3679-B13)
  • Bundesministerium für Wissenschaft, Forschung und Wirtschaft
  • Svenska Sällskapet för Medicinsk Forskning
  • Karolinska Institutet
  • Stockholms Läns Landsting (ALF‐2011‐0279, ALF‐2011‐0260, ALF2011-0260 and ALF-2011-0279)
  • Vetenskapsrådet (349-2007-8703, K2013-65X-06816-30-4, K2009-65X-2233-01-3)
  • Österreichische Forschungsförderungsgesellschaft (843536, K-Project Nr. 843536)
  • Bundesministerium für Verkehr, Innovation und Technologie
  • Novo Nordisk Fonden (NNF15SA0018346)
  • Standortagentur Tirol
  • Wirtschaftsagentur Wien
  • Provincia autonoma di Bolzano - Alto Adige
  • Menzies Centre for Australian Studies, King's College London, University of London
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cerebrovascular and Carotid Artery Diseases
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
Keywords
carotid plaque, vulnerable plaque, biomarker signatures, symptomatic carotid disease, MMP-9, S100A8/S100A9, cathepsin D, LGALS3BP, YKL-40, fibronectin, vascular smooth muscle cells, carotid endarterectomy, cardiovascular risk prediction, Bruneck Study
MeSH terms
Carotid Artery Diseases, Cells, Cultured, Extracellular Matrix, Female, Humans, Male, Biomarkers, Extracellular Matrix Proteins, Endarterectomy, Carotid, Proteome, Myocytes, Smooth Muscle, Proteomics, Atherosclerosis, Plaque, Atherosclerotic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Extracellular matrix proteomics identifies molecular signature of symptomatic carotid plaques. https://app.cochat.ai/papers/10.1172/jci86924
The paper
Langley, S. R., Willeit, K., Didangelos, A., Matic, L. P., Skroblin, P., Barallobre-Barreiro, J., Lengquist, M., Rungger, G., Kapustin, A., Kedenko, L., Molenaar, C., Lu, R., Barwari, T., Suna, G., Yin, X., Iglseder, B., Paulweber, B., Willeit, P., Shalhoub, J., . . . Mayr, M. (2017). Extracellular matrix proteomics identifies molecular signature of symptomatic carotid plaques. Journal of Clinical Investigation. https://doi.org/10.1172/jci86924

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.